Features associated with germline CDKN2A mutations: A GenoMEL study of melanoma-prone families from three continents

Journal of Medical Genetics

Volumn 44, Issue 2, 2007, Pages 99-106

  Goldstein, Alisa M ^a   Chan, May ^b   Harland, Mark ^b   Hayward, Nicholas K ^c   Demenais, Florence ^d   Bishop, D Timothy ^b   Azizi, Esther ^e   Bergman, Wilma ^f   Bianchi Scarra, Giovanna ^g   Bruno, William ^g   Calista, Donato ^h   Cannon Albright, Lisa A ⁱ   Chaudru, Valerie ^d   Chompret, Agnes ^j   Cuellar, Francisco ^k   Elder, David E ^l   Ghiorzo, Paola ^g   Gillanders, Elizabeth M ^m   Gruis, Nelleke A ^a   Hansson, Johan ⁿ   Hogg, David ^o   Holland, Elizabeth A ^p   Kanetsky, Peter A ^l   Kefford, Richard F ^p   Landi, Maria Teresa ^a   Lang, Julie ^q   Leachman, Sancy A ^r   MacKie, Rona M ^q   Magnusson, Veronica ⁿ   Mann, Graham J ^p   Bishop, Julia Newton ^b   Palmer, Jane M ^c   Puig, Susana ^k   Puig Butille, Joan A ^k   Stark, Mitchell ^c   Tsao, Hensin ^s   Tucker, Margaret A ^a   Whitaker, Linda ^b   Yakobson, Emanuel ^e   Ingvar, Christian ^t   Borg, Ake ^t   Westerdahl, Johan ^t   Masback, Anna ^t   Olsson, Hakan ^t   Malvehy, Josep ^k   Badenas, Celia ^k   Cervera, Remedios ^k   Martí, Rosa ^u   Brunet Vidal, Joan ^v,w   Yang, Guang ^s   Martin, Nicholas ^c   Whiteman, David ^c   Green, Adele ^c   Aitken, Joanne ^x   Minghetti, Paola ^h   Mantelli, Michela ^g   Pastorino, Lorenza ^g   Nasti, Sabina ^g   Gargiulo, Sara ^g   Gliori, Sara ^b   Mistry, Sushila ^y   Randerson Moor, Juliette ^y   De Snoo, Femke A ^f   Ter Huurne, Jeanet A C ^f   Van Der Rhee, Jasper ^f   Van Mourik, Leny ^f   Van Nieuwpoort, Frans ^f   Van Der Drift, Clasine ^z   Bressac De Paillerets, Brigitte ^j   Avril, Marie Francoise ^aa   Grange, F ^ab   Sassolas, B ^ab   Boitier, F ^ab   Chevrant Breton, J ^ab   Lasset, C ^ab   Dugast, C ^ab   Vabres, P ^ab   Ganguly, Arupa ^l   Ming, Michael ^l   Van Belle, Patricia ^l   Platz, Anton ⁿ   Egyhazi, Suzanne ⁿ   Tuominen, Rainer ⁿ   Linden, Diana ⁿ   Schmid, Helen ^ac   Scope, Alon ^e   Pavlotsky, Felix ^e   Friedman, Eitan ^e   Eliason, Mark ^r   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^d UNIVERSITÉ D EVRY VAL D ESSONNE   (France)

^e TEL AVIV UNIVERSITY   (Israel)

^f LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF GENOA   (Italy)

^h BUFALINI HOSPITAL   (Italy)

ⁱ UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^j INSTITUT GUSTAVE ROUSSY   (France)

^k HOSPITAL CLÍNIC   (Spain)

^l UNIVERSITY OF PENNSYLVANIA   (United States)

^m NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

ⁿ KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^o UNIVERSITY OF TORONTO   (Canada)

^p UNIVERSITY OF SYDNEY   (Australia)

^q UNIVERSITY OF GLASGOW   (United Kingdom)

^r UNIVERSITY OF UTAH   (United States)

^s MASSACHUSETTS GENERAL HOSPITAL   (United States)

^t LUND UNIVERSITY HOSPITAL   (Sweden)

^u UNIVERSITY OF LLEIDA   (Spain)

^v HOSPITAL UNIVERSITARI SANT JOAN DE REUS   (Spain)

^w Hospital Trueta   (Spain)

^x CANCER COUNCIL QUEENSLAND   (Australia)

^y UNIVERSITY OF GENOA   (Italy)

^z Netherlands Foundation for the Detection of Hereditary Tumors   (Netherlands)

^aa Queensland Cancer Fund ^*  (France)

^ab French Hereditary Melanoma Study Group   (France)

^ac WESTMEAD HOSPITAL   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 2A; UNCLASSIFIED DRUG;

ARTICLE; CLINICAL FEATURE; CLINICAL STUDY; CONTROLLED STUDY; FAMILY HISTORY; GENE MUTATION; GENETIC RISK; GERM LINE GENE THERAPY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; MULTIVARIATE ANALYSIS; PANCREAS CANCER; PRIORITY JOURNAL;

EID: 33847282821     PISSN: 00222593     EISSN: None     Source Type: Journal    
DOI: 10.1136/jmg.2006.043802     Document Type: Article

References (48)

1. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003;22:3053-62.
2. Bergman W, Watson P, deJong J, Lynch HT, Fusaro RM. Systemic cancer and the FAMMM syndrome. Br J Cancer 1990;61:932-6.
3. Bergman W, Gruis N. Correspondence: familial melanoma and pancreatic cancer. N Engl J Med 1996;334:471.
4. INK4 mutations. N Engl J Med 1995;333:970-4.
5. Goldstein AM. Familial melanoma, pancreatic cancer and germline CDKN2A mutations. Hum Mut 2004;23:630 [Mutation in Brief #718].
6. Soufir N, Avril M-F, Chompret A, Demenais F, Bombled J, Spatz A, Stoppa-Lyonnet D, the French Familial Melanoma Study Group, Benard J, Bressac-de Paillerets B. Prevalence of p16 and CDK4 germline mutations in 48 melanoma-prone families in France. Hum Mol Genet 1998;7:209-16.
7. Kefford RF, Newton-Bishop JA, Bergman W, Tucker MA on behalf of the Melanoma Genetics Consortium. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17:3245-51.
8. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, McLaughlin J, Hogg D, Lassam NJ. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998;338:879-87.
9. MacKie RM, Andrew N, Lanyon WG, Connor JM. CDKN2A germline mutations in U.K. patients with familial melanoma and multiple primary melanomas. J Invest Dermatol 1998;111:269-72.
10. Holland EA, Schmid H, Kefford RF, Mann GJ. CDKN2A. (p16INK4a) and CDK4 mutation analysis in 131 Australian melanoma probands: effect of family history and multiple primary melanomas, Genes Chromosomes Cancer, 1999;25:1-10.
11. Ghiorzo P, Ciotti P, Mantelli M, Heouaine A, Queirolo P, Rainere ML, Ferrari C, Santi PL, De Marchi R, Farris A, Ajmar F, Bruzzi P, Bianchi-Scarra G. Characterization of Ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999;83:441-8.
12. Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Masback A, Westerdahl J, Olsson H, Ingvar C. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst 2000;92:1260-6.
13. Vasen HFA, Gruis NA, Fronts RR, van der Velden PA, Hille ETM, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16-Leiden). Int J Cancer 2000;87:809-11.
14. Parker J, Florell SR, Alexander A, DiSario JA, Shami PJ, Leachman SA. Pancreatic carcinoma surveillance in patients with familial melanoma. Arch Dermatol 2003;139:1019-25.
15. Puig S, Malvehy J, Badenas C, Ruiz A, Jimenez D, Cuellar F, Azon A, Gonzàlez U, Castel T, Campoy A, Herrero J, Martí R, Brunet-Vidal J, Milà M. Role of the CDKN2A locus in patients with multiple primary melanomas. J Clin Oncol 2005;23:3043-51.
16. Niendorf K, Goggins W, Yang G, Tsai K, Shennan M, Bell D, Sober A, Hogg D, Tsao H. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. J Med Genet 2006;43:501-6.
17. Begg CB, Orlow I, Hummer AJ, Armstrong BK, Kricker A, Marrett LD, Millikan RC, Gruber SB, Anton-Culver H, Zanetti R, Gallagher RP, Dwyer T, Rebbeck TR, Mitra N, Busam K, From L, Berwick M for the Genes Environment and Melanoma (GEM) Study Group. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. J Natl Cancer Inst 2005;97:1507-15.
18. Yang G, Niendorf KB, Tsao H. A novel methionine-53-valine mutation of p16 in a hereditary melanoma kindred. J Invest Dermatol 2004;123:574-5.
19. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
20. Goldstein AM, Struewing JP, Chidambaram A, Fraser MC, Tucker MA. Genotype-phenotype relationships in American melanoma-prone families with CDKN2A and CDK4 mutations. J Natl Cancer Inst 2000;92:1006- 10.
21. Eliason MJ, Larson AA, Florell SR, Zone JJ, Cannon-Albright LA, Samlowski WE, Leachman SA. Population-based prevalence of CDKN2A mutations in Utah melanoma families. J Invest Dermatol 2006;126:660-6.
22. Puig S, Ruiz A, Castel T, Volpini V, Malvehy J, Cardellach F, Lynch M, Mascaro JM, Estivill X. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a mutation in the CDKN2A (p16INK4A) gene. Human Genet 1997;101:359-64.
23. Ruiz A, Puig S, Malvehy J, Lazaro C, Lynch M, Gimenez-Arnau AM, Puig U, Sanchez-Conejo J, Estivill X, Castel T. CDKN2A mutations in Spanish cutaneous malignant melanoma families and patients with multiple melanomas and other neoplasia. J Med Genet 1999;36:490-4.
24. Rizos H, Puig S, Badenas C, Malvehy J, Darmanian AP, Jimenez L, Mila M, Kefford RF. A melanoma-associated germline mutation in exon 1β inactivates p14ARF. Oncogene 2001;20:5543-7.
25. Yakobson E, Eisenberg S, Isacson R, Halle D, Levy-Lahad E, Catane R, Safro M, Sobolev V, Huot T, Peters G, Ruiz A, Malvehy J, Puig S, Chompret A, Avril MF, Shafir R, Peretz H, Paillerets BB. A single Mediterranean, possibly Jewish, origin for the Val59Gly CDKN2A mutation in four melanoma-prone families. Eur J Hum Genet 2003;11:288-96.
26. Landi MT, Goldstein AM, Tsang S, Munroe D, Modi W, Ter-Minassian M, Steighner R, Dean M, Metheny N, Staats B, Agatep R, Hogg D, Calista D. Genetic susceptibility in familial melanoma from North Eastern Italy. J Med Genet 2004;41:557-66.
27. Lang J, Boxer M, MacKie RM. CDKN2A. mutations in Scottish families with cutaneous melanoma: results from 32 newly identified families, Br J Dermatol, 2005;153:1121-5.
28. Harland M, Holland EA, Ghiorzo P, Mantelli M, Bianchi-Scarra G, Goldstein AM, Tucker MA, Ponder BAJ, Mann GJ, Bishop DT, Bishop JN. Mutation screening of the CDKN2A promoter in melanoma families. Genes Chromosomes Cancer 2000;28:45-57.
29. Newton Bishop JA, Harland M, Bennett DC, Bataille V, Goldstein AM, Tucker MA, Ponder BAJ, Cuzick J, Selby P, Bishop DT. Mutation testing in melanoma families: INK4A, CDK4, and INK4D. Br J Cancer 1999;80:295-300.
30. Newton Bishop JA, Wachsmuth RC, Harland M, Bataille V, Pinney E, Mack P, Baglietto L, Cuzick J, Bishop DT. Genotype/phenotype and penetrance studies in melanoma families with germline CDKN2A mutations. J Invest Dermatol 2000;114:28-33.
31. Bergman W, Gruis NA, Frants RR. The Dutch FAMMM family material - Clinical and genetic data. Cytogenet Cell Genet 1992;59:161-4.
32. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR. Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995;10:351-3.
33. Kannegiesser C, Avril M-F, Spatz A, Laud K, Lenoir GM, Bressac-de Paillerets. CDKN2A as a uveal and cutaneous melanoma susceptibility gene. Genes Chromosomes Cancer 2003;38:265-8.
34. Chaudru V, Chompret A, Bressac-de Paillerets B, Spatz A, Avril M-F, Demenais F. Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unseleded by family history and in melanoma-prone families. J Natl Cancer Inst 2004;96:785-95.
35. Borg A, Johannsson U, Johannson O, Hakansson S, Westerdahl J, Masback A, Olsson H, Ingvar C. Novel germline p16 mutation in familial malignant melanoma in southern Sweden. Cancer Res 1996;56:2497-500.
36. Plate A, Hansson J, Mansson-Brahme E, Lagerlof B, Linder S, Lundqvist E, Sevigny P, Inganas M, Ringborg U. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997;89:697-702.
37. Plato A, Hansson J, Ringborg U. Screening of germline mutations in the CDK4, CDKN2C, and TP53 genes in familial melanoma: a clinic-based population study. Int J Cancer 1998;78:13-15.
38. Hashemi J, Linder S, Platz A, Hansson J. Melanoma development in relation to non-functional p16/INK4A protein and dysplastic nevus syndrome in Swedish melanoma kindreds. Melanoma Res 1999;9:21-30.
39. Walker GJ, Hussussian C, Flores JF, Glendening JM, Haluska FG, Dracopoli NC, Hayward NK, Fountain JW. Mutations of the CDKN2/p16INK4 gene in Australian melanoma kindreds. Hum Molec Genet 1995;4:1845-52.
40. Flores JF, Pollock PM, Walker GJ, Glendening JM, Lin AHT, Palmer JM, Walters MK, Hayward NK, Fountain JW. Analysis of the CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Oncogene 1997;15:2999-3005.
41. Whiteman DC, Milligan A, Welch J, Green AC, Hayward NK. Germline CDKN2A mutations in childhood melanoma. J Natl Cancer Inst 1997;89:1460.
42. Aitken J, Welch J, Duffy D, Milligan A, Green A, Martin N, Hayward N. CDKN2A variants in a population-based sample of queensland families with melanoma. J Natl Cancer Inst 1999;91:446-52.
43. Holland EA, Beaton SC, Becker TM, Grulet OMC, Peters BA, Rizos H, Kefford RF, Mann GJ. Analysis of the p16 gene, CDKN2, in 17 Australian melanoma kindreds. Oncogene 1995;11:2289-94.
44. Rizos H, Becker TM, Holland EA, Kefford RF, Mann GJ. Differential expression of p16(INK4a) and p16 beta transcripts in B-lymphoblastoid cells from members of hereditary melanoma families without CDKN2A exon mutations. Oncogene 1997;15:515-23.
45. Parkin DM, Whelan SL, Ferlay J, Storm H. Cancer Incidence in Five Continents. Vol I to VIII. CANCERMondial, http://www-dep.iarc.fr; Lyon, IARC CancerBase No, 7, 2005;(France).
46. Schottenfeld D, Fraumeni JF, Jr. Cancer epidemiology and prevention, 2nd edn., New York, NY: Oxford University Press, 1996.
47. Shafey O, Dolwick S, Guindon GE, eds. Tobacco control country Profiles, 2003. Atlanta, GA: American Cancer Society, 2003.
48. Goldstein AM, Tucker MA. Editorial: a piece of the melanoma puzzle. J Natl Cancer Inst 2005;97:1486-7.